MindMed is a clinical stage biopharma company specializing in developing psychedelic-based and novel treatments for brain health disorders. Publicly traded under $MNMD and $MMED, it advances innovative therapies in mental health. With a following of nearly 24,000, MindMed demonstrates growing influence in the emerging field of psychedelic therapeutics.

‌